August 31 (SeeNews) - Bulgarian medical consumables producer Etropal [BUL:ETR] said that it generated a consolidated net profit of 128,000 levs ($71,252/65,445 euro) in the first six months of this year, compared with a net loss of 592,000 levs in the same period of 2022.
Etropal's total revenue grew to some 4.9 million levs in the review period from 3.8 million levs a year ago, the company said in an interim financial statement on Tuesday.
Operating expenses edged up to 4.8 million levs from 4.4 million levs in the prior-year period, but higher expenses for materials and external services were offset by a decrease in cost of goods sold.
Based in Etropole, western Bulgaria, Etropal is part of diversified group Synthetica [BUL:SYN] and makes medical consumables used for hemodialysis.
Shares in Etropal closed at 5.00 levs in the company's most recent trading session on the Bulgarian stock exchange on Wednesday.
(1 euro = 1.95583 levs)